About The Study: This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net prices of new anti-obesity medications are essential to ensure equitable access to highly effective anti-obesity medications.
Corresponding Author: To contact the corresponding author, Jennifer H. Hwang, DO, email jennifer.hwang2@bsd.uchicago.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2024.5586)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.5586?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031425
JAMA Health Forum